Thompson speaking at AAPS 2020 PHARMSCI 360
Sep 14, 2020
Between newly developed products, strategic partnerships, and acquisitions in the Advanced Therapy Medicinal (ATMP) market, companies are racing to find or create capacity for plasmids, viral vectors, gene-modified cell therapies, and fill finish products.
Owner companies and entrepreneurs are considering building multi-product or multi-modal ATMP facilities to meet this emerging demand. They are also looking at how to “future proof” their investment so that it works for next generation manufacturing processes.
A dedicated manufacturing facility can be costly, and limits options for the future. Why not have a facility that can produce multiple product types and allows for adaptability to an evolving product pipeline?
- What the future of the “flexible facility” truly looks like for companies with multi-product types.
- How to reduce the risk of cross-contamination in a multi-product facility.
- How to “future proof” your design to leverage developments in closed and automated processing.
- How to scale appropriately to achieve faster speed-to-market, lower costs and ultimate manufacturing flexibility.
October 26-November 5, 2020
Wednesday, November 4, 2020
12:00 PM – 12:30 PM EST